Dark | Light
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![USCorpFilings Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1859110030752313345.png) SEC Filings Digest [@USCorpFilings](/creator/twitter/USCorpFilings) on x 4389 followers
Created: 2025-06-26 20:30:11 UTC

$CRNX Product Expansion:

On June 26, 2025, Crinetics Pharmaceuticals hosted an R&D Day to share updates on its drug development pipeline, including promising preclinical data on treatments for Graves' disease and autosomal dominant polycystic kidney disease. The event highlighted key developments in their early-stage pipeline assets and future clinical strategies.




XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1938333994040303804/c:line.svg)

**Related Topics**
[sec](/topic/sec)
[$crnx](/topic/$crnx)

[Post Link](https://x.com/USCorpFilings/status/1938333994040303804)

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

USCorpFilings Avatar SEC Filings Digest @USCorpFilings on x 4389 followers Created: 2025-06-26 20:30:11 UTC

$CRNX Product Expansion:

On June 26, 2025, Crinetics Pharmaceuticals hosted an R&D Day to share updates on its drug development pipeline, including promising preclinical data on treatments for Graves' disease and autosomal dominant polycystic kidney disease. The event highlighted key developments in their early-stage pipeline assets and future clinical strategies.

XXX engagements

Engagements Line Chart

Related Topics sec $crnx

Post Link

post/tweet::1938333994040303804
/post/tweet::1938333994040303804